NCT06588478: An ongoing trial by Loxo Oncology, Inc.
This trial is ongoing. It must report results 3 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06588478 |
|---|---|
| Title | A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 3, 2025 |
| Completion date | June 30, 2028 |
| Required reporting date | June 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |